VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering

VOLITIONRX LTD

Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.
Each unit contains one share and one warrant; warrants exercisable at $0.60, 5-year term, cashless basis if no registration.
Pre-offering cash and cash equivalents estimated at only $0.3M as of September 30, 2025.
Offering closed October 14, 2025; directors and officers purchased 254,229 units on same terms.
Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential strategic acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.